David A. Siegel Cardiol Therapeutics Inc. Transaction History
Two Sigma Advisers, LP
- $47 Billion
- Q3 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Cardiol Therapeutics Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 32,608 shares of CRDL stock, worth $33,260. This represents 0.0% of its overall portfolio holdings.
Number of Shares
32,608Holding current value
$33,260% of portfolio
0.0%Shares
9 transactions
Others Institutions Holding CRDL
# of Institutions
52Shares Held
7.39MCall Options Held
25KPut Options Held
0-
Tejara Capital LTD London, X02.63MShares$2.68 Million1.47% of portfolio
-
Advisor Shares Investments LLC Bethesda, MD557KShares$568,5350.11% of portfolio
-
Bank Of America Corp Charlotte, NC551KShares$562,0740.0% of portfolio
-
Marshall Wace, LLP London, X0544KShares$555,2030.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il463KShares$472,7310.0% of portfolio
About Cardiol Therapeutics Inc.
- Ticker CRDL
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 61,942,500
- Market Cap $63.2M
- Description
- Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate t...